Q-omics provides the consensus-scored BTBD10P2 profile across patient tissues and cancer cell-line models. BTBD10P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BTBD10P2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, BTBD10P2 RNA expression shows 16,219 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where BTBD10P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD10P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD10P2 survival associations across molecular data types. BTBD10P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD10P2 RNA expression–survival associations across cancer types. High BTBD10P2 expression shows unfavorable associations in KIRC, KICH, LIHC, KIRP and STAD, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BTBD10P2 RNA expression.
This table summarizes BTBD10P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BTBD10P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD10P2 shows higher tumor expression in HNSC, LUAD, COAD, STAD, LUSC and LIHC. The HNSC box plot shows higher BTBD10P2 RNA expression in tumor versus normal tissue (log2 FC = +0.364, t-test p < 0.001).
This table shows molecular features associated with BTBD10P2 in patient tissues and cancer cell lines. In patient samples, BTBD10P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
